Furthermore, metformin treatment of two primary breast cancer cells MBCDF and MBCD17 downregulated mesenchymal signature genes vimentin and SNAIL and inactivated NFKB and STAT3 signaling pathways in response to IL-6 [41]. The gene discussed is STAT3; the disease is breast cancer.